Copyright
©The Author(s) 2019.
World J Gastroenterol. Mar 21, 2019; 25(11): 1341-1354
Published online Mar 21, 2019. doi: 10.3748/wjg.v25.i11.1341
Published online Mar 21, 2019. doi: 10.3748/wjg.v25.i11.1341
Figure 3 Expression of CD73 in a signaling lymphocytic activation molecule family, member 7-expression colorectal cancer cell line.
High-through imaging and results of CD73(+)/signaling lymphocytic activation molecule family, member 7 (SLAMF7)(+) at day 0 and day 5 of co-culture with THP-1 monocytes, THP-1 M2 macrophages, and lipopolysaccharide activated THP-1. On day 5, expression of CD73 was significantly lower than day 0 in the SLAMF7-expressing region. SLAMF7: Signaling lymphocytic activation molecule family, member 7; LPS: Lipopolysaccharide; CRC: Colorectal cancer.
- Citation: Lee JL, Roh SA, Kim CW, Kwon YH, Ha YJ, Kim SK, Kim SY, Cho DH, Kim YS, Kim JC. Clinical assessment and identification of immuno-oncology markers concerning the 19-gene based risk classifier in stage IV colorectal cancer. World J Gastroenterol 2019; 25(11): 1341-1354
- URL: https://www.wjgnet.com/1007-9327/full/v25/i11/1341.htm
- DOI: https://dx.doi.org/10.3748/wjg.v25.i11.1341